The influence of azelnidipine on plasma renin activity and plasma aldosterone concentration in hypertensive patients.

The influence of azelnidipine on plasma renin activity and plasma aldosterone concentration in hypertensive patients. - The influence of azelnidipine on PRA and PAC in HT.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001739

Enrollment

Registered

2009-02-27

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

PRA/PAC was measured in 10 of essential hypertensive patients. Then, 16 mg of azelnidipine a day was started to administer for 4 weeks. After this period, PRA/PAC was measured again. PRA/PAC was meas

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Systolic blood pressure ; more than 140 mmHg or diastolic blood pressure; more than 90 mmHg

Exclusion criteria

Exclusion criteria: Secondary hypertension

Design outcomes

Primary

Measure	Time frame
Plasma renin activity, plasma aldosterone concentration	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026